Although the world is becoming mostly sedentary, our bodies still require a wide variety of daily movements in order to work well. Many of us struggle to get regular exercise, but even that can fall short of nourishing the body from head to toe. How can we move more—a lot more—when we have sore, stiff parts and overly busy lifestyles? Join Katy Bowman M.S., biomechanist, author, and movement educator as she combines big-picture lessons on biomechanics, kinesiology, physiology, and natural hu ...
…
continue reading
Indhold leveret af AUAUniversity and American Urological Association. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af AUAUniversity and American Urological Association eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.
Player FM - Podcast-app
Gå offline med appen Player FM !
Gå offline med appen Player FM !
Adjuvant Therapies for High-Risk Non-Metastatic Kidney Cancer
MP3•Episode hjem
Manage episode 392223880 series 2497848
Indhold leveret af AUAUniversity and American Urological Association. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af AUAUniversity and American Urological Association eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.
The AUA Expert Exchange Podcast: Discussions in Managing GU Cancer: Adjuvant Therapies for High-Risk Non-Metastatic Kidney Cancer CME Available: https://auau.auanet.org/node/39542 Release Date: December, 2023 Expiration Date: December, 2024 LEARNING OBJECTIVES: At the conclusion of this activity, participants will be able to: 1. Identify the rationale behind using adjuvant therapies in high-risk non-metastatic kidney cancer and the goals of adjuvant treatment. 2. Describe the adjuvant therapies that have been investigated to date for high-risk non-metastatic kidney cancer, including targeted therapies, immunotherapies, and combination approaches. 3. Discuss the challenges and limitations associated with adjuvant therapy trials in high-risk non-metastatic kidney cancer, such as patient selection, trial design, and long-term follow-up. ACKNOWLEDGEMENTS: Support provided by independent educational grants from: AstraZeneca Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Lantheus Medical Imaging Merck & Co., Inc.
…
continue reading
341 episoder
MP3•Episode hjem
Manage episode 392223880 series 2497848
Indhold leveret af AUAUniversity and American Urological Association. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af AUAUniversity and American Urological Association eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.
The AUA Expert Exchange Podcast: Discussions in Managing GU Cancer: Adjuvant Therapies for High-Risk Non-Metastatic Kidney Cancer CME Available: https://auau.auanet.org/node/39542 Release Date: December, 2023 Expiration Date: December, 2024 LEARNING OBJECTIVES: At the conclusion of this activity, participants will be able to: 1. Identify the rationale behind using adjuvant therapies in high-risk non-metastatic kidney cancer and the goals of adjuvant treatment. 2. Describe the adjuvant therapies that have been investigated to date for high-risk non-metastatic kidney cancer, including targeted therapies, immunotherapies, and combination approaches. 3. Discuss the challenges and limitations associated with adjuvant therapy trials in high-risk non-metastatic kidney cancer, such as patient selection, trial design, and long-term follow-up. ACKNOWLEDGEMENTS: Support provided by independent educational grants from: AstraZeneca Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Lantheus Medical Imaging Merck & Co., Inc.
…
continue reading
341 episoder
Alle Folgen
×Velkommen til Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.